These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Targeted therapy with bevacizumab and erlotinib tailored to the molecular profile of patients with recurrent glioblastoma. Preliminary experience. D'Alessandris QG; Montano N; Cenci T; Martini M; Lauretti L; Bianchi F; Larocca LM; Maira G; Fernandez E; Pallini R Acta Neurochir (Wien); 2013 Jan; 155(1):33-40. PubMed ID: 23132371 [TBL] [Abstract][Full Text] [Related]
4. High-dose antiangiogenic therapy for glioblastoma: less may be more? de Groot JF Clin Cancer Res; 2011 Oct; 17(19):6109-11. PubMed ID: 21852387 [TBL] [Abstract][Full Text] [Related]
5. Is there a role for bevacizumab in the treatment of glioblastoma? Chi AS; Chamberlain MC Oncologist; 2013; 18(10):1080-2. PubMed ID: 24056893 [TBL] [Abstract][Full Text] [Related]
6. Erlotinib plus bevacizumab is effective in EGFR-mutant NSCLC. Cancer Discov; 2014 Nov; 4(11):OF18. PubMed ID: 25367959 [TBL] [Abstract][Full Text] [Related]
7. Neuro-oncology: What is the optimal use of bevacizumab in glioblastoma? Desjardins A Nat Rev Neurol; 2015 Aug; 11(8):429-30. PubMed ID: 26195258 [No Abstract] [Full Text] [Related]
8. Salvage with erlotinib plus bevacizumab: not in NSCLC. Sculier JP; Meert AP; Berghmans T Lancet; 2011 May; 377(9780):1810-2. PubMed ID: 21621709 [No Abstract] [Full Text] [Related]
10. World's first delivery of intra-arterial bevacizumab directly into brain tumor of glioblastoma multiforme patients. Expert Rev Anticancer Ther; 2010 Jan; 10(1):5. PubMed ID: 20014880 [No Abstract] [Full Text] [Related]
11. Bevacizumab and recurrent malignant gliomas: a European perspective. Wick W; Weller M; van den Bent M; Stupp R J Clin Oncol; 2010 Apr; 28(12):e188-9; author reply e190-2. PubMed ID: 20159801 [No Abstract] [Full Text] [Related]
12. Bevacizumab for newly diagnosed glioblastoma. Chinot OL; Wick W; Cloughesy T N Engl J Med; 2014 May; 370(21):2049. PubMed ID: 24860870 [No Abstract] [Full Text] [Related]
14. Bevacizumab in glioblastoma--still much to learn. Fine HA N Engl J Med; 2014 Feb; 370(8):764-5. PubMed ID: 24552324 [No Abstract] [Full Text] [Related]
16. Phase I/II study of oral erlotinib for treatment of relapsed/refractory glioblastoma multiforme and anaplastic astrocytoma. Kesavabhotla K; Schlaff CD; Shin B; Mubita L; Kaplan R; Tsiouris AJ; Pannullo SC; Christos P; Lavi E; Scheff R; Boockvar JA J Exp Ther Oncol; 2012; 10(1):71-81. PubMed ID: 22946346 [TBL] [Abstract][Full Text] [Related]
17. Enigma of a rapid introduction of antiangiogenic therapy with bevacizumab in glioblastoma: a new era in the treatment of malignant brain tumours? Henriksson R; Bergström P; Johansson M; Sandström M Acta Oncol; 2009; 48(1):6-8. PubMed ID: 18932097 [No Abstract] [Full Text] [Related]
18. [From ASCO and WCLC 2005 to the clinical practice: targeted therapies]. Pérol M Rev Pneumol Clin; 2006 Feb; 62 Spec no 1():1S30-4. PubMed ID: 16719154 [No Abstract] [Full Text] [Related]
19. Complete regression of choroidal metastasis secondary to non-small-cell lung cancer with intravitreal bevacizumab and oral erlotinib combination therapy. Kim SW; Kim MJ; Huh K; Oh J Ophthalmologica; 2009; 223(6):411-3. PubMed ID: 19628953 [TBL] [Abstract][Full Text] [Related]